Where We Work

A Global Effort

Our Country Partners

In 2024 we partnered with 36 countries (or regions) in Africa, Asia, the Middle East, South America, and the Western Pacific to distribute Mectizan® for the elimination of onchocerciasis (also known as river blindness) and lymphatic filariasis (LF). A total of 406.1 million treatments were approved. This total included 274.2 million treatments of Mectizan (donated by Merck & Co., Inc.) for river blindness, 42.9 million treatments for LF (Mectizan + albendazole [donated by GSK]), 52.8 million treatments in 14 countries implementing “triple therapy” for LF*, and 36.2 million treatments in countries where LF and river blindness are co-endemic. 

*Triple therapy is also known as IDA, which stands for ivermectin (Mectizan), diethylcarbamazine (DEC, donated by Eisai), and albendazole.

Mectizan has been sent to 62 countries since the donation was announced in 1987.

Country/Territory Status
American Samoa LF treatment ongoing
Angola River blindness & LF treatment ongoing
Benin River blindness treatment ongoing; LF in post-treatment surveillance
Brazil River blindness treatment ongoing
Burkina Faso River blindness & LF treatment ongoing
Burundi River blindness treatment ongoing
Cameroon River blindness treatment ongoing; LF in post-treatment surveillance
Central African Republic River blindness & LF treatment ongoing
Chad River blindness & LF treatment ongoing
Colombia River blindness eliminated
Comoros LF in post-treatment surveillance
Congo River blindness & LF treatment ongoing
Côte d'Ivoire River blindness & LF treatment ongoing
Democratic Republic of the Congo River blindness & LF treatment ongoing
Ecuador River blindness eliminated
Egypt LF eliminated (Mectizan was used to clear up hotspots after Egypt was validated to be free of LF)
Equatorial Guinea LF treatment ongoing
Eritrea LF in post-treatment surveillance
Ethiopia River blindness & LF treatment ongoing
Fiji LF treatment ongoing
French Polynesia LF treatment ongoing
Gabon River blindness & LF treatment not started
Ghana River blindness & LF treatment ongoing
Guatemala River blindness eliminated
Guinea River blindness & LF treatment ongoing
Guinea-Bissau River blindness & LF treatment ongoing
Guyana LF treatment ongoing
Haiti LF treatment ongoing
India LF treatment ongoing
Indonesia LF treatment ongoing
Kenya LF in post-treatment surveillance
Liberia River blindness & LF treatment ongoing
Madagascar LF treatment ongoing
Malawi River blindness treatment ongoing; LF eliminated
Malaysia LF treatment ongoing
Maldives LF treatment ongoing to address LF infections detected during post-validation surveillance
Mali River blindness treatment ongoing; LF in post-treatment surveillance
Mexico River blindness eliminated
Mozambique River blindness & LF treatment ongoing
Myanmar LF treatment ongoing
Nepal LF treatment ongoing
New Caledonia LF treatment ongoing
Niger River blindness eliminated; LF treatment ongoing
Nigeria River blindness & LF treatment ongoing
Papua New Guinea LF treatment ongoing
Philippines LF treatment ongoing
Samoa LF treatment ongoing
Sao Tome and Príncipe LF in post-treatment surveillance
Senegal River blindness in post-treatment surveillance; LF treatment ongoing
Sierra Leone River blindness & LF treatment ongoing
South Sudan River blindness & LF treatment ongoing
Sudan River blindness & LF treatment ongoing
Tanzania River blindness & LF treatment ongoing
Timor-Leste LF eliminated
Togo River blindness treatment ongoing; LF eliminated
Tonga LF treatment ongoing to address LF infections detected during post-validation surveillance
Tuvalu LF treatment ongoing
Uganda River blindness treatment ongoing; LF in post-treatment surveillance
Venezuela River blindness treatment ongoing
Wallis and Futuna LF treatment ongoing to address LF infections detected during post-validation surveillance
Yemen River blindness treatment ongoing; LF eliminated
Zimbabwe LF treatment ongoing